Veradermics Incorporated
MANE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MANE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MANE
Veradermics Incorporated is a clinical-stage biopharmaceutical company with no approved products, focused on developing VDPHL01 as its lead candidate, and holding $319.3M in cash as of June 30, 2026.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$4.09B
Cash Runway
164.9 moLead Asset
vdphl01 (Phase 2)
Next Catalyst
Phase3_Topline · Sep 1, 2026Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 5 clinical trials · 3 catalysts for Veradermics Incorporated.
Veradermics Incorporated is a clinical-stage biopharmaceutical company with no approved products, focused on developing VDPHL01 as its lead candidate, and holding $319.3M in cash as of June 30, 2026.
- Veradermics is a clinical-stage biopharmaceutical company with no products approved for commercial sale [sec · filed 2026-04-27].
- As of June 30, 2026, the company reported cash & equivalents of $319.3M, net income of -$23.5M, and shareholders' equity of -$76.1M [sec].
- The company's lead product candidate is VDPHL01, and its success depends on the approval and commercialization of this candidate [sec · filed 2026-04-27].
- Veradermics completed an IPO in Q1 2026 with gross proceeds of $294.8M and a subsequent Public Offering and Private Placement in May 2026 with gross proceeds of $472.0M [sec_mda · as of 2026-05-12].
What works
- The company has a substantial cash position of $319.3M as of June 30, 2026, which management believes will fund operations into 2030 [sec_mda · as of 2026-08-11].
- Veradermics successfully completed an IPO and additional offerings in 2026, raising significant capital to support its clinical programs [sec_mda · as of 2026-05-12].
- The company has no ongoing material financing commitments such as lines of credit or guarantees that would affect liquidity over the next five years [sec_mda · as of 2026-08-11].
What to weigh
- Veradermics has incurred substantial losses since inception and anticipates incurring substantial and increasing losses for the foreseeable future [sec · filed 2026-04-27].
- The company will require substantial additional financing to achieve its goals, and failure to obtain capital on acceptable terms could delay or terminate product development [sec · filed 2026-04-27].
- Clinical development costs are expected to increase significantly with ongoing trials, and the inherently unpredictable nature of clinical development poses risks [sec_mda · as of 2026-08-11].
- The company has negative shareholders' equity of -$76.1M as of June 30, 2026, indicating accumulated deficits [sec].
From the filings
Quoted directly from source documents.
Veradermics is a clinical-stage biopharmaceutical company with no approved products.
“We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale.”
SEC filings · April 27, 2026
The company's success depends on VDPHL01.
“We currently anticipate that our success will depend on the approval and successful commercialization of VDPHL01, which is our lead product c”
SEC filings · April 27, 2026
Cash position of $319.3M as of June 30, 2026.
“As of June 30, 2026, we had $819.9 million of cash, cash equivalents and marketable securities.”
SEC MD&A · August 11, 2026
The company expects to need substantial additional capital.
“We will need to raise substantial additional capital in the future.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2026-09-01 · Phase3_Topline — Topline data from a randomized, double-blind, placebo-controlled Phase 3 study of VDPHL01.
- 2027-07-01 · Phase3_Topline — Topline data from a second Phase 3 study of VDPHL01.
- 2028-01-01 · Phase3_Topline — Topline data from a third Phase 3 study of VDPHL01.
Risks & what to watch (4)›
Key risks
- No approved products — Veradermics has no products approved for commercial sale and relies on successful development of VDPHL01 [sec · filed 2026-04-27].
- Substantial additional capital needed — The company will require substantial additional financing to achieve its goals; failure to obtain capital could delay or terminate development [sec · filed 2026-04-27].
- Clinical development uncertainty — Clinical trials are inherently unpredictable, and costs are expected to increase significantly with ongoing trials [sec_mda · as of 2026-08-11].
- Negative shareholders' equity — As of June 30, 2026, shareholders' equity was -$76.1M, reflecting accumulated deficits [sec].
What to watch
- Topline data from Phase 3 trials of VDPHL01 expected in September 2026, July 2027, and January 2028 [upcoming catalysts].
- Cash burn rate and any updates to cash runway guidance in future SEC filings [sec_mda · as of 2026-08-11].
- Progress in enrollment and completion of ongoing clinical trials for VDPHL01 [sec_mda · as of 2026-08-11].
- Any additional financing activities or partnerships to support development [sec · filed 2026-04-27].
Sources: SEC filings · SEC MD&A · Generated August 24, 2026 · How we verify sources →
Run Veradermics Incorporated through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Veradermics Incorporated facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
164.9 months
D/E 0.01 · 0% dilution
Lead: Phase 2
1 candidate
3 upcoming, next in ~2d
0 buys · 15 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$1.37B
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 4,168,970 | $263.3M |
| citadel advisors llc | 1,825,672 | $115.3M |
| fmr llc | 1,792,909 | $113.2M |
| viking global investors lp | 1,690,555 | $106.8M |
| vanguard capital management llc | 1,399,290 | $88.4M |
| adage capital partners gp, l.l.c. | 1,100,000 | $69.5M |
| woodline partners lp | 1,001,292 | $63.2M |
| infinitum asset management, llc | 731,149 | $46.2M |
| marshall wace, llp | 654,601 | $41.3M |
| vivo capital, llc | 600,000 | $37.9M |
Showing top 10 of 77 institutional holders of Veradermics Incorporated. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 7.9%
- Days to cover
- 3.4
- Shares short
- 1,790,324
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MANE short interestFrequently asked questions
What is the AI investment thesis for Veradermics Incorporated?
Veradermics Incorporated is a clinical-stage biopharmaceutical company with no approved products, focused on developing VDPHL01 as its lead candidate, and holding $319.3M in cash as of June 30, 2026.
What is Veradermics Incorporated's lead drug candidate?
Veradermics Incorporated's most advanced tracked candidate is vdphl01 (Phase 2) for Androgenetic Alopecia.
What is Veradermics Incorporated's next catalyst?
Veradermics Incorporated's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-dose Study to Evaluate the Eff" — expected September 1, 2026.
Who is the CEO of Veradermics Incorporated?
Dr. Reid Waldman M.D. is the chief executive officer of Veradermics Incorporated (MANE).
Where is Veradermics Incorporated headquartered?
Veradermics Incorporated (MANE) is headquartered in New Haven, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.